Key Takeaways
- Shares of VolitionRx (VNRX) climbed more than 70% during Wednesday’s pre-market session
- VolitionRx announced successful isolation of circulating tumor DNA (ctDNA) at over 99% purity from blood samples
- The breakthrough technology, dubbed Capture-Seq™, employs a dual-phase approach merging physical enrichment with bioinformatics analysis
- Performance data revealed 49 out of 49 cancer cases identified in one blinded cohort, plus 13 out of 14 in another
- VolitionRx referenced a combined addressable market worth approximately $36 billion and is engaging with prospective licensing partners
Shares of VNRX skyrocketed over 70% during Wednesday’s pre-market session following VolitionRx’s announcement of what the company characterized as a transformative advancement in liquid biopsy technology.
The biotechnology firm reported successful isolation of circulating tumor-derived DNA (ctDNA) from patient blood samples achieving purity levels above 99%. This achievement means virtually all non-cancerous DNA was eliminated, producing an exceptionally clean sample of tumor-specific DNA.
Liquid biopsy technology has historically faced a fundamental obstacle: the vast majority of cell-free DNA present in bloodstream originates from normal, healthy cells rather than malignant ones. Extracting a reliable cancer signal from this biological noise represents an enormous technical challenge. VolitionRx claims its innovative approach overcomes this hurdle.
The proprietary technique, branded as Capture-Seq™, operates through a two-phase mechanism. Initially, it performs physical enrichment of the sample. Subsequently, sophisticated bioinformatics processing eliminates residual interference. According to the company, this produces a dataset exceeding 99% pure ctDNA.
Jake Micallef, Chief Scientific Officer, described the achievement as “a world-first.” He explained that CTCF-bound DNA — the particular DNA biomarker this methodology isolates — is virtually nonexistent in healthy plasma while being almost exclusively cancer-derived in patients with malignancies.
“Removal of background normal cell free DNA from the blood to reveal this level of tumor derived DNA has been a long-term goal of liquid biopsy,” Micallef said in the company’s release.
Performance Data From Blinded Research Cohorts
VolitionRx disclosed findings from two separate blinded cohort investigations. The first cohort showed perfect detection: all 49 cancer cases were correctly identified. The second cohort demonstrated 13 successful detections out of 14 cases.
These figures represent preliminary-stage data, and both cohorts are relatively small. More extensive clinical studies will be required before any potential commercial launch. Additionally, the methodology captures only a specific subset of ctDNA, meaning certain tumor fragments might escape detection.
VolitionRx has submitted an updated research manuscript to Research Square, which operates as a preprint repository. The publication has not yet undergone peer review, representing the standard validation process before findings gain acceptance within the broader scientific establishment.
Commercial Opportunity and Market Landscape
VolitionRx referenced a combined total addressable market valued at roughly $36 billion, encompassing both multi-cancer early detection (MCED) applications and minimal residual disease (MRD) monitoring capabilities.
According to company statements, VolitionRx is presently conducting active negotiations with potential diagnostic licensing partners. No formal agreements have been disclosed to date.
VNRX stock appeared positioned to close above its 100-day moving average for the first time since October 8, 2025, assuming pre-market momentum carried through to regular trading hours.
The revised preprint manuscript is anticipated to appear on Research Square in the near term, based on company communications.
